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Summary 1 
Due to anticipated clinical benefits, moving targets are potential future indications for pencil beam 2 
scanned proton therapy (PBS-PT). However, currently they are not widely treated at PBS-PT facilities 3 
due to dosimetric uncertainties caused by motion. We developed a method, the 4D robustness 4 
evaluation method (4DREM), to realistically and efficiently assess all possible events impacting PBS-5 
PT treatments in the thorax. Using the 4DREM in large cohorts of lung and oesophageal cancer 6 
patients, it will become possible to illustrate, in clinical practice, how to trigger robustness settings 7 
for plan optimisation and to select and apply motion mitigation techniques.  8 
1. Introduction 9 
Compared to conventional radiotherapy, pencil beam scanned proton therapy (PBS-PT) has 10 
demonstrated considerable clinical benefit for numerous tumour sites [1]. The high conformity 11 
achievable with PBS-PT allows higher tumour dose delivery (improving local control) and lower dose 12 
to adjacent healthy tissue, due to a lower integral dose [2]. These benefits of PBS-PT are extremely 13 
important for the treatment of moving targets, such as thoracic cancers (4D treatments), due to the 14 
critical structures surrounding the tumour (healthy lung and oesophagus tissue, heart, and spinal 15 
cord). Therefore, despite the fact that 4D PBS-PT is not currently widely used, moving targets are 16 
increasingly being considered for the near future at dedicated proton facilities. 17 
Due to the finite range of protons and their sensitivity to variations in water equivalent thickness, the 18 
robustness of PBS-PT treatment plans may be compromised by small changes to the planning 19 
situation [3]. To a small extent, machine errors occurring during the treatment delivery (influencing 20 
spot position, delivered monitor units per spot, spot energy, and absolute time point of spot delivery) 21 
can result in deviations in the delivered dose from the clinical planned dose distribution, which has 22 
been calculated by the treatment planning system (TPS) and approved by the radiation oncologist. 23 
Moreover, deviation in the patient treatment position from the planned position can have a 24 
pronounced dosimetric impact. Finally, anatomical variations within the patient throughout the 25 
treatment course may result in density variations along the proton beam path, which can cause 26 
range errors. Particularly for thoracic treatment sites, motion due to respiration can disturb the 27 
planned dose distribution on delivery. 28 
Despite the presence of respiratory motion, treatment planning is performed on a snapshot 29 
representation of the patient, resulting in differences between the planned and delivered dose 30 
distribution. For PBS-PT in the thorax region especially, dose inhomogeneities may arise within the 31 
target due to the interference of the time structure of delivery and target motion due to the 32 
patient’s respiration pattern (interplay effects) [4]. 33 
Previous studies have analysed and reported the robustness of PBS-PT plans to setup and range 34 
errors for non-moving targets [5–10]. Regarding PBS-PT for moving targets, Knopf et al. [11] 35 
exhaustively assessed the impact of interplay effects on planned dose distributions for liver tumours 36 
by including the timeline of the delivery in the TPS process. With the aim of comparing different 37 
optimisation strategies, Liu et al. [12] examined the combined influence of setup and range 38 
uncertainties and respiratory motion on lung cancer intensity-modulated proton therapy (IMPT) 39 
plans. Robustness evaluation studies on mediastinal lymphoma patient cases (against inter- and 40 
intra-fractional uncertainties and interplay effects) were performed by Zeng et al. [13,14]. Lin et al. 41 
[15] investigated the effect of motion, range errors, and patient setup variations in a treatment-42 
planning comparison study. They compared double scattering and single-field uniform dose (SFUD) 43 
proton therapy for stage III locally advanced non-small cell lung cancer (NSCLC) patients. However, in 44 
this study the impact of machine errors and interplay was not evaluated in combination with the 45 
other afore mentioned effects. Finally, Inoue et al. [16] developed a method to evaluate robust 46 
optimised IMPT plans for stage III NSCLC patients. This robustness evaluation tool considered the 47 
impact of setup and range errors, breathing motion, and interplay. However, the impact of the 48 
combination of interplay with setup and range errors, or the machine errors, was not incorporated. 49 
Furthermore, only the interplay per energy layer and not per spot, was considered. Other more 50 
recent studies also evaluated the robustness of different types of lung cancer IMPT treatment plans 51 
to setup and range uncertainties, and separately, breathing motion and interplay effects [17,18]. 52 
This study arose as a follow-up of the publication by Inoue et al. [16], and so in this technical note we 53 
report on the development and application of a more comprehensive and refined tool. With our new 54 
4D robustness evaluation method (4DREM), it is now possible to assess the impact of all the above-55 
mentioned PBS-PT effects simultaneously. The 4DREM is essential to safely extend PBS-PT to thoracic 56 
indications. It allows the assessment of full PBS-PT treatment courses for moving targets, helping to 57 
define an optimal clinical protocol for this group of patients. 58 
2. Materials and methods 59 
2.1. Effects of 4D PBS-PT  60 
Our 4DREM was implemented using in-house developed Python scripts, through features available in 61 
the RayStation TPS (RaySearch Laboratories, Stockholm, Sweden). Setup and range errors were 62 
simulated using representative values from literature [10]. Furthermore, potential machine errors, 63 
anatomy changes, breathing motion, and interplay effects occurring during treatment delivery were 64 
considered based on treatment-plan specific delivery-machine log files and 4DCT imaging data (see 65 
Fig. 1A). 66 
2.1.1. Setup and range errors 67 
Fourteen scenario dose distributions (representing 14 possible full treatment courses) were 68 
simulated. For each scenario, eight fractions were taken into account [15]. The accumulated setup 69 
error effect on the dose for a fractionated treatment was simulated by defining a systematic and 70 
random (day-to-day) fraction of this error. In particular, systematic setup errors were simulated by 71 
shifting the planning isocentre in 14 different x, y, and z directions (vertices and faces of a cube). The 72 
fractionation effect was considered by randomly picking, for each fraction per scenario, an additional 73 
isocentre translation by sampling a normal distribution. Range errors were simulated by randomly 74 
applying a perturbation of 0 or ± 3 % on the CT densities [19]. Due to the systematic nature of range 75 
uncertainty, for all fractions of the same scenario, the same range error was considered [20]. 76 
2.1.2. Machine errors, anatomy changes, breathing motion, and interplay effects 77 
From dry run deliveries of the calculated dose distributions, machine log files were obtained. The 78 
nominal plan was split into sub-plans using a dedicated script that retrieves information from the 79 
delivery log files (spot position, dose, and energy and the absolute time of delivery). Subsequently, 80 
machine errors, anatomy changes, breathing motion, and interplay effects were simultaneously 81 
included by calculating sub-plan dose distributions on particular 4DCT phases. The 4D dose was 82 
accumulated on the planning 4DCT as well as on repeated 4DCTs (acquired in successive weeks 83 
during the course of radiotherapy). To split the delivery into sub-plans, a constant breathing cycle of 84 
5 s was assumed [21]. The 4D dose accumulation in each of the available 4DCTs was performed by 85 
warping the sub-plan dose distributions per phase onto the end-of-exhalation planning CT phase. The 86 
warped doses were subsequently summed together. The deformable image registration (DIR) 87 
algorithm used for the dose warping (and contour propagation), called ANACONDA (Anatomically 88 
Constrained Deformation Algorithm), is included in the TPS [22]. For all DIRs, the delineated clinical 89 
target volumes (CTVs) were used as controlling regions of interest (ROIs). This ensured that the 90 
alignment of these contours in the registered image pairs drove the deformation [23]. 91 
2.1.3. Combination - 4D robustness evaluation method (4DREM) 92 
The 4DREM makes it possible to combine the evaluation of setup and range errors with machine 93 
errors, anatomy changes, breathing motion, and interplay effects. For this study, a dose distribution 94 
was calculated per sub-plan, on a particular phase of a particular 4DCT set, considering setup and 95 
range errors. A fraction dose was calculated by applying the same setup and range errors to all sub-96 
plan doses of the specific 4DCT and summing the phase-specific contributions. For each fraction 97 
calculation, the 4DCT starting phase of the delivery was randomly selected. Finally, the entire 98 
treatment course dose distribution was obtained by performing dose accumulation of several 99 
fraction doses based on different 4DCTs. In total, 14 4D accumulated scenario doses were obtained, 100 
each representing a possible treatment course of a particular nominal plan (Fig. 1A). 101 
2.2. Application to patient data 102 
IMPT plans using five times layered rescanning for a sample lung cancer patient (NSCLC stage III) and 103 
a sample oesophageal cancer patient were created in RayStation version 6.99 using the Monte Carlo 104 
dose engine. Both patients had previously been treated at the UMCG with conventional photon 105 
radiotherapy. 106 
The minimax robust optimisation approach was used, aiming for robustness against ± 3 % range 107 
uncertainties and setup uncertainties between 5.0 mm and 7.5 mm [19]. For both sample patients, a 108 
3D robust optimised plan (created on the averaged planning CT) and a 4D robust optimised plan 109 
(created on the end-of-exhalation planning CT phase) were generated. For the 4D robust plan, all 110 
planning 4DCT phases were used during the optimisation [24]. Three beam directions were used for 111 
both 3D and 4D robust optimised plans for the NSCLC case (one left-posterior oblique and two right-112 
posterior oblique fields). For the oesophagus case, two beam directions (posterior-anterior and right-113 
posterior oblique) were chosen. A nominal dose was prescribed in terms of relative biological 114 
effectiveness (RBE), 60.00 GyRBE in 25 fractions (lung case) and 41.40 GyRBE in 23 fractions 115 
(oesophagus case) to the internal clinical target volume (iCTV) in the 3D robust optimisation and to 116 
the CTV in the 4D robust optimisation. For each patient, to ensure a fair plan comparison, the 117 
difference in fulfilled median dose to the target (prescribed structure) between 3D and 4D plans, was 118 
within 0.5 Gy. A density override to muscle tissue (1.050 g/cm3) was applied within the iCTV for the 119 
3D robust optimisation. For the oesophagus case, the feeding tube and contrast were also delineated 120 
and an override applied of the same mass density value as muscle tissue. 121 
All nominal plans created were visually inspected by physicians and medical physicists (regarding 122 
beam arrangements, overrides, adequate target coverage, and minimisation of organs-at-risk [OARs] 123 
dose). Preliminary robustness evaluation was then performed on the averaged planning CT towards 124 
setup and range errors alone. If target coverage in the minimum dose per voxel over all scenarios 125 
(voxel-wise worst-case [minimum] dose distribution) was acceptable (D98(iCTV) ≥ 95 % of prescribed 126 
dose), the plans were delivered in dry runs at our proton facility to obtain log files. The in-air spot 127 
sigma at our beam line ranges from 6.5 mm to 3.0 mm for proton energies from 70 MeV to 230 MeV. 128 
For both patients, a planning 4DCT and five weekly repeated 4DCT scans (each with ten phases) were 129 
available. The iCTVs were delineated on the averaged planning CT (volumes of 153.2 cm3 and 399.7 130 
cm3 for the lung and oesophageal cancer patients, respectively), taking into account all breathing 131 
phases. Gross tumour volumes (GTVs) and CTVs were defined on all image phases by contour 132 
propagation and subsequent correction by an experienced physician. Motion amplitudes were given 133 
by the mean of all the deformation vector lengths within the CTV resulting from DIR between the 134 
end-of-exhalation and end-of-inhalation phases of a particular 4DCT [16]. Averaged over all six 135 
4DCTs, the motion amplitudes were 4.0 ± 0.8 mm (lung case) and 6.5 ± 0.9 mm (oesophagus case). 136 
Sub-plans (derived from the delivery log files) and all available 4DCT scans were used to evaluate the 137 
treatment plans by the 4DREM. The available 4DCTs were distributed and equally weighted through 138 
the eight evaluated fractions. For the first two fractions, 4D dose accumulation of sub-plan doses was 139 
performed on the planning 4DCT, for the subsequent two fractions the first repeated 4DCT was used, 140 
and for the last four fractions the remaining repeated 4DCTs were successively selected (Fig. 1A). 141 
Plan robustness to the combined disturbing effects was evaluated by the 4DREM on the end-of-142 
exhalation planning CT phase through the voxel-wise worst-case dose distribution (obtained from the 143 
14 scenario doses) [25,26]. The dose-volume histogram (DVH) of the CTV and respective metrics (V95 144 
and homogeneity index [D2-D98]) were examined in the voxel-wise worst-case dose distribution. The 145 
voxel-wise worst-case dose was computed as the maximum dose per voxel over all scenarios (voxel-146 
wise worst-case [maximum]) for D2, and for V95 and D98 as the minimum. Additionally, the OAR DVH 147 
indices Dmean(heart), D1(spinal cord), and Dmean(lungs-GTV) were averaged over all scenarios resulting 148 
from the execution of the 4DREM, and extracted for all plans. 149 
3. Results 150 
The voxel-wise worst-case dose distributions obtained from the 4DREM were used to assess the 151 
robustness of 3D and 4D robust optimised IMPT treatment plans of a lung and an oesophageal 152 
cancer patients. Robustness was calculated for the combination of the disturbing effects expected 153 
when treating moving targets with PBS-PT. For the oesophagus 4D plan, we computed the DVHs of 154 
CTV, heart, spinal cord, and lungs-GTV for the nominal case and all treatment scenarios resulting 155 
from the 4DREM, and the corresponding voxel-wise worst-case dose (Fig. 1B). Small differences 156 
between nominal and voxel-wise worst-case dose distributions were observed for the 3D and 4D 157 
robust optimised plans for both sample patients (Table 1). 158 
4. Discussion 159 
Our 4DREM allows for the assessment of the robustness of PBS-PT plans by simulating setup and 160 
range errors in combination with machine errors, anatomy changes, breathing motion, and interplay 161 
effects. Compared to previous work, our method presents a more comprehensive, and hence more 162 
representative, evaluation [11–18]. Furthermore, the most recent Monte Carlo dose engine of the 163 
TPS was used instead of the less accurate Pencil Beam algorithm, the latter which over-predicts the 164 
dose delivered to the target for proton dose calculations in lung [27]. 165 
The influence of DIR motion estimation uncertainties on the dose accumulation of the 4DREM is 166 
rather limited. The selected DIR method (ANACONDA) was validated geometrically and dosimetrically 167 
in a previous collaboration study from our group for liver cases [28]. In this work the use of 168 
controlling ROIs in the application of DIR provided improved results. Therefore, for the 4DREM, the 169 
CTV is used as controlling ROI in order to improve accuracy around that targeted area. Additionally, 170 
multiple-field treatment plans and five times layered rescanning were used, which in our previous 171 
paper demonstrated to mitigate the DIR induced dosimetric errors for 4D PBS-PT. 172 
The impact of fractionation is incorporated in the 4DREM by the simulation of a random setup error, 173 
dose accumulation performed in different 4DCTs, and de-synchronisation of the starting phase from 174 
fraction-to-fraction. By including the fractionation effect, the smoothening out of the dose over the 175 
treatment course is taken into account. Eight evaluated fractions (instead of the clinical delivery in 25 176 
lung and 23 oesophageal radiotherapy fractions) were considered in order to reduce computation 177 
time. It has been shown that limiting the fraction number to eight is representative of the fraction-178 
smearing effect of inhomogeneities in the target dose distribution for NSCLC PBS-PT [15]. 179 
Six 4DCTs were available for both sample patients (a planning 4DCT and five repeated 4DCTs). 180 
Considering that multiple 4DCTs in the 4DREM already partially takes into account patient inter-181 
fractional setup errors, only the remaining setup uncertainty needed to be added. Therefore, the 182 
proton isocentre vs. imaging isocentre accuracy, the patient re-positioning error, and the intra-183 
fractional variability of patient bony anatomy (as quantified by Sonke et al. [29] for lung tumours 184 
using 4D cone beam CT scans) were estimated. The result was 2 mm remaining setup uncertainty, 185 
which was incorporated in the 4DREM in the simulated setup shifts. These shifts were calculated by 186 
scaling the systematic and random errors as in the treatment margin recipe provided by van Herk et 187 
al. [30]. 188 
Hoffmann et al. [31] demonstrated that large anatomical changes can lead to target under-dosage in 189 
IMPT of advanced lung cancer. Inter-fractional variability was included in this study through multiple 190 
4DCTs. However, one should not forget the intrinsic limitations of 4DCT reconstruction. By 191 
considering an average breathing cycle, and neglecting any irregularity of the breathing pattern 192 
within one fraction, the accuracy of 4D dose calculations can be compromised. Furthermore, the 193 
number of different 4DCTs taken into account can have an influence on the 4DREM results. Future 194 
work will exploit the inclusion of more 4D information throughout radiotherapy, especially modelling 195 
intra-fractional motion, which could be extracted from CBCT images, camera-based systems or, in the 196 
future, from non-additional imaging dose techniques such as 4DMRI [32]. 197 
In this technical note we present results of the 4DREM application for two representative patients 198 
with intra-thoracic tumours, who could be future candidates to be treated at our proton facility. As a 199 
proof-of-concept, we have shown that both the planning protocol and subsequent delivery of 3D and 200 
4D PBS-PT plans were clinically suitable; the 4DREM did not reveal any robustness shortcomings. This 201 
means that the optimisation parameters used and/or the application of rescanning as a motion 202 
mitigation technique were effective strategies for these patients. However, the question remains 203 
whether the applied optimisation/motion mitigation might have resulted in an overly conservative 204 
plan. The next step will include a larger patient cohort study with 20 patients (ten lung and ten 205 
oesophagus cases) with extensive numbers of repeated 4DCT datasets. This will allow for general 206 
conclusions concerning the impact of the disturbing effects of PBS-PT in the treatment of moving 207 
targets. In previous studies, 4D robust optimisation produced more robust and interplay-effect-208 
resistant plans for targets of NSCLC cases than 3D optimisation [24]. Since the use of 4D robust 209 
optimisation implies more manual work and optimisation time within clinical workflow, we hope to 210 
estimate the benefits of this complex process in terms of plan robustness for a more representative 211 
number of cases, and to be able to generate a patient selection tool that can identify the need for 3D 212 
vs. 4D robust optimisation. 213 
The great potential benefit of PBS-PT is the high conformity (allowing high doses to the tumour while 214 
sparing surrounding tissue). However, this feature of PBS-PT brings challenges for moving targets, 215 
requiring a high degree of treatment plan robustness. Therefore, comprehensive evaluation 216 
methods, such as the 4DREM for thoracic lesions treated with PBS-PT, enable:  217 
 The establishment of an optimal clinical protocol, when used for subsequent treatment plan 218 
comparison studies. This allows the selection of optimisation strategies and helps to 219 
determine the need for additional motion mitigation techniques. 220 
 Treatment planning confidence by testing plan robustness, which can eventually increase the 221 
number of proton centres performing these treatments in the future. 222 
 Patient-specific quality assessment of future 4D adaptive workflows. 223 
  
 Fig. 1. A: Schematic representation of a treatment scenario simulated through the 4DREM for PBS-
PT. B: Application results of the 4DREM in the 4D robust optimised IMPT plan created for the sample 
oesophageal cancer patient. B.I: Voxel-wise worst-case (minimum) dose distribution resultant from 
the inclusion of the combined 4D PBS-PT disturbing effects. In white is the delineated CTV and the 
light blue line shows the 95 % isodose. B.II: Heart, spinal cord, lungs-GTV, and CTV DVH curves for the 
nominal plan and all 14 simulated treatment scenarios (in the same coloured transparent lines), and 
resultant DVH(CTV) for the voxel-wise worst-case (minimum). 
 
 
Table 1 Extracted nominal, scenarios, and voxel-wise worst-case dose distribution statistics for the 3D and 4D robust optimised plans of the sample NSCLC and 
oesophageal cancer patients. 
                                  
     Dose statistics   




    
Dmean(heart)  
D1(spinal cord)  
Dmean(lungs-GTV)  
V95([i]CTV) D2-D98([i]CTV) 





                 Sample 














(mean ± SD) 
 
(mean ± SD) 
 






4.65 5.90 ± 0.36 
 
39.93 39.44 ± 2.35 
 
9.40 9.83 ± 0.20 
 




2.52 3.10 ± 0.28 
 
31.61 38.02 ± 3.02 
 
10.47 10.68 ± 0.16 
 
99.89 100.00 3.84 3.90 




11.28 14.45 ± 1.44 
 
31.13 31.39 ± 0.22 
 
4.30 4.35 ± 0.06 
 




10.96 15.01 ± 1.36 
 
33.91 33.95 ± 0.13 
 
4.28 4.53 ± 0.06 
 
100.00 99.99 2.35 2.55 
 Abbreviations: 3D = 3D robust optimised plan; 4D = 4D robust optimised plan; D2-D98 = homogeneity index. 
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